Eastgate Biotech Corp: 10-Q filed 2018-08-17

Name: Eastgate Biotech Corp: 10-Q filed 2018-08-17
Creator: Eastgate Biotech Corp

What Eastgate Biotech Corp reported in its quarterly report filed 2018-08-17 (fiscal Q1 2017): 19 published measures, 36 facts as tagged in accession 0001563228-18-000018.

This filing

Form: 10-Q (quarterly report)
Filed: 2018-08-17
Fiscal period: fiscal Q1 2017
Accession: 0001563228-18-000018 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Eastgate Biotech Corp filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-03-31	9,348	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2017-03-31	4,934,134	USD
At 2016-12-31	4,618,066	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-952,111	USD	90
2016-01-01 to 2016-03-31	-1,463,516	USD	91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-121,479	USD	90
2016-01-01 to 2016-03-31	-103,503	USD	91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	141,966	USD	90
2016-01-01 to 2016-03-31	92,104	USD	91

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-03-31	-15,583,102	USD
At 2016-12-31	-14,630,991	USD

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-03-31	9,348	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	-37,424	USD	90
2016-01-01 to 2016-03-31	-35,336	USD	91

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-03-31	4,894,110	USD
At 2016-12-31	4,578,042	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2017-03-31	423,705	USD
At 2016-12-31	312,475	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	914,688	USD	90
2016-01-01 to 2016-03-31	1,243,778	USD	91

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	175,990	USD	90
2016-01-01 to 2016-03-31	138,641	USD	91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-03-31	322,872,175	shares
At 2016-12-21	309,522,175	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-03-31	10,626,491	USD
At 2016-12-31	9,970,127	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit	Days
At 2017-03-31	-4,924,786	USD
At 2016-12-31	-4,618,066	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2017-03-31	2,590,890	USD
At 2016-12-31	2,528,834	USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	635,941	USD	90
2016-01-01 to 2016-03-31	1,032,220	USD	91

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	37,424	USD	90
2016-01-01 to 2016-03-31	219,738	USD	91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2017-01-01 to 2017-03-31	111,229	USD	90
2016-01-01 to 2016-03-31	-15,127	USD	91

Inspect the source

Entity: Eastgate Biotech Corp / CIK 0001099574
Captured: 2026-09-22 19:38 UTC
SEC response SHA-256: c76fb31ad9e6a591ce49245f912371413b5720c281a157c432746a7cf121003d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001099574.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))